RxDoctor Payments Data

Natasha Sparrow, DO

Epilepsy · Spokane, WANPI 1326308339

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 97.7% of the total across 47 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 13 manufacturers reported payments, led by Livanova USA, Inc. at 26.6% of the total. Reporting peaked in 2024 at $487 and has fallen 59.2% since, to $199 in 2025.

$1,135in general payments, 2019–2025

Across 47 payments — averaging $24.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Livanova USA, Inc.$302
  • UCB, Inc.$198
  • AbbVie$125
  • SK Life Science, Inc.$110
  • Neuropace, Inc.$94
  • Sumitomo Pharma America, Inc.$77
  • plus $229 from 7 others

What the payments were for

  • Food & beverage$1,10998%
  • Education$262%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

Too few epilepsy providers in Washingtonto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$154,636
Medicare patients
596
Services billed
1,233

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FinteplaFenfluramine Hcl37$543,943
EpidiolexCannabidiol (Cbd)50$197,820
BriviactBrivaracetam57$82,146
Lacosamide350$39,866
Levetiracetam822$26,079
Trokendi XrTopiramate26$19,858
DepakoteDivalproex Sodium21$18,615
Levetiracetam ErLevetiracetam177$17,837
Lamotrigine519$15,118
ZonisadeZonisamide13$14,845
Lamotrigine ErLamotrigine73$14,532
FycompaPerampanel13$14,460
Clobazam127$10,688
NayzilamMidazolam15$10,295
Zonisamide136$8,149

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
UCB, Inc.Fintepla, Briviact, Nayzilam$198$636,384109 claims
PfizerDilantin$24$1,82127 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few epilepsy providers in Washingtonon file to place this against a meaningful peer group, so we don't.

Other epilepsy in Spokane

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →